Background and aims: Remdesivir is an antiviral drug that is widely used in patients with Covid-19. The aim of this study was to review the systematic review and meta-analysis studies of Remdesivir in patients with Covid-19.
Methods: An electronic search was conducted in PubMed, Scopus, Cochrane Library, and Web of Science databases up to December 2021. In addition, other databases were searched. A manual search of studies and other sources was also conducted to find evidence. The tool (Overview Quality Assessment Questionnaire) was used to evaluate the quality of articles.
Results: Seventeen systematic review and meta-analysis studies were included in the study. The results showed that Remdesivir in seven studies reduced the mortality of patients with Covid-19 and in seven other studies had no effect on reducing patient mortality compared to the control group. Other findings of the study also showed that Remdesivir increased clinical improvement, increased clinical recovery, reduced clinical recovery time, and accelerated the discharge time of patients with Covid-19 from the hospital. Side effects were well tolerated in most studies in the Remdesivir group. Adverse events were mild and moderate in most studies in the Remdesivir group.
Conclusion: The findings of the study showed that the mortality rate in patients treated with remedsivir in studies is different, so it is better to use this drug with caution. Adverse events were well tolerated.